ARM fosters investment, research & development, commercialization, and access to safe, effective, and transformational treatments and cures.
Innovation in Released August 6, ARM’s H1 2020 Global Regenerative Medicine & Advanced Therapies Sector Report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic. The sector is poised for record-breaking financings in 2020, with several notable policy wins in the first half. Most importantly, patients are continuing to benefit from these transformative therapies.
This spring, ARM hosted experts on biotech fundraising, market access, value-based therapies, clinical trials amidst the pandemic, and cell therapies to treat COVID-19 as a part of a webinar series on timely sector issues.
Produced by the Marwood Institute and funded by ARM, this report uses a “Transformative Therapy Value Model,” and demonstrates that durable cell or gene therapies for multiple myeloma, sickle cell disease, and hemophilia A could provide cumulative cost-savings of $33B over the next ten years.
ARM CEO Janet Lambert discusses milestones from the cell and gene therapy sector over the past year and gives an update on the current financial, clinical, and policy environment for these innovative therapies.
Potentially curative cell and gene therapies are changing the face of medicine and providing hope to patients where there was once none. But how will they be paid for? This webinar discusses the implementation of value-based payment models for innovative therapies.
The webinar includes discussion around how COVID-19 changes the way we think about healthcare decision making and places intense pressure on financial management at all levels of the health system.
This webinar highlights potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, presented on their treatment approaches and plans for near term clinical trials.
All Videos & Recordings
